Expression and regulation of the ΔN and TAp63 isoforms in salivary gland tumorigenesis clinical and experimental findings
- PMID: 21703418
- PMCID: PMC3123859
- DOI: 10.1016/j.ajpath.2011.03.037
Expression and regulation of the ΔN and TAp63 isoforms in salivary gland tumorigenesis clinical and experimental findings
Abstract
The TP63 gene, a TP53 homologue, encodes for two main isoforms by different promoters: one retains (TA) and the other lacks (ΔN) the transactivation domain. p63 plays a critical role in the maintenance of basal and myoepithelial cells in ectodermally derived tissues and is implicated in tumorigenesis of several neoplastic entities. However, the biological and regulatory roles of these isoforms in salivary gland tumorigenesis remain unknown. Our results show a reciprocal expression between TA and ΔN isoforms in both benign and malignant salivary tumors. The most dominantly expressed were the ΔN isoforms, whereas the TA isoforms showed generally low levels of expression, except in a few tumors. High ΔNp63 expression characterized tumors with aggressive behavior, whereas tumors with high TAp63 expression were significantly smaller and less aggressive. In salivary gland cells, high expression of ΔNp63 led to enhanced cell migration and invasion and suppression of cell senescence independent of TAp63 and/or TP53 gene status. We conclude the following: i) overexpression of ΔNp63 contributes to salivary tumorigenesis, ii) ΔNp63 plays a dominant negative effect on the TA isoform in the modulation of cell migration and invasion, and iii) the ΔN isoform plays an oncogenic role and may represent an attractive target for therapeutic intervention in patients with salivary carcinomas.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Figures




Similar articles
-
Differential expression of p63 isotypes (DeltaN and TA) in salivary gland neoplasms: biological and diagnostic implications.Hum Pathol. 2005 Jul;36(7):821-7. doi: 10.1016/j.humpath.2005.05.014. Hum Pathol. 2005. PMID: 16084953
-
p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue.J Thorac Oncol. 2011 Mar;6(3):473-81. doi: 10.1097/JTO.0b013e31820b86b0. J Thorac Oncol. 2011. PMID: 21289519
-
ΔNp63 to TAp63 expression ratio as a potential molecular marker for cervical cancer prognosis.PLoS One. 2019 Apr 11;14(4):e0214867. doi: 10.1371/journal.pone.0214867. eCollection 2019. PLoS One. 2019. PMID: 30973901 Free PMC article.
-
A double dealing tale of p63: an oncogene or a tumor suppressor.Cell Mol Life Sci. 2018 Mar;75(6):965-973. doi: 10.1007/s00018-017-2666-y. Epub 2017 Oct 3. Cell Mol Life Sci. 2018. PMID: 28975366 Free PMC article. Review.
-
Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls.Histopathology. 2024 Apr;84(5):723-741. doi: 10.1111/his.15101. Epub 2023 Nov 27. Histopathology. 2024. PMID: 38012539 Review.
Cited by
-
Development of a New Swine Model Resembling Human Empty Nose Syndrome.Medicina (Kaunas). 2024 Sep 24;60(10):1559. doi: 10.3390/medicina60101559. Medicina (Kaunas). 2024. PMID: 39459347 Free PMC article.
-
p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.Virchows Arch. 2018 Mar;472(3):351-359. doi: 10.1007/s00428-018-2324-2. Epub 2018 Feb 27. Virchows Arch. 2018. PMID: 29484502
-
15-hydroxyprostaglandin dehydrogenase-derived 15-keto-prostaglandin E2 inhibits cholangiocarcinoma cell growth through interaction with peroxisome proliferator-activated receptor-γ, SMAD2/3, and TAP63 proteins.J Biol Chem. 2013 Jul 5;288(27):19484-502. doi: 10.1074/jbc.M113.453886. Epub 2013 May 16. J Biol Chem. 2013. Retraction in: J Biol Chem. 2015 Nov 20;290(47):28353. doi: 10.1074/jbc.A113.453886. PMID: 23687300 Free PMC article. Retracted.
-
Arsenic suppresses cell survival via Pirh2-mediated proteasomal degradation of ΔNp63 protein.J Biol Chem. 2013 Feb 1;288(5):2907-13. doi: 10.1074/jbc.M112.428607. Epub 2012 Dec 27. J Biol Chem. 2013. PMID: 23271742 Free PMC article.
-
The microRNA feedback regulation of p63 in cancer progression.Oncotarget. 2015 Apr 20;6(11):8434-53. doi: 10.18632/oncotarget.3020. Oncotarget. 2015. PMID: 25726529 Free PMC article. Review.
References
-
- Pinkston J.A., Cole P. Incidence rates of salivary gland tumors: results from a population-based study. Otolaryngol Head Neck Surg. 1999;120:834–840. - PubMed
-
- Speight P.M., Barrett A.W. Salivary gland tumours. Oral Dis. 2002;8:229–240. - PubMed
-
- Terhaard C.H., Lubsen H., Van der Tweel I., Hilgers F.J., Eijkenboom W.M., Marres H.A., Tjho-Heslinga R.E., de Jong J.M., Roodenburg J.L., Dutch Head and Neck Oncology Cooperative Group Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastasis, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck. 2004;26:681–692. discussion, 692–693. - PubMed
-
- Day T.A., Deveikis J., Gillespie M.B., Joe J.K., Ogretmen B., Osguthorpe J.D., Reed S.G., Richardson M.S., Rossi M., Saini R., Sharma A.K., Stuart R.K. Salivary gland neoplasms. Carr Treat Options Oncol. 2004;5:11–26. - PubMed
-
- Bron L.P., Traynor S.J., McNeil E.B., O'Brien C.J. Primary and metastatic cancer of the parotid: comparison of clinical behavior in 232 cases. Laryngoscope. 2003;113:1070–1075. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous